Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE versus NADOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE versus NADOLOL.
LABETALOL HYDROCHLORIDE vs NADOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a non-selective beta-adrenoceptor blocker and selective alpha-1 adrenoceptor blocker. It reduces myocardial contractility, heart rate, and peripheral vascular resistance.
Non-selective beta-adrenergic receptor antagonist (beta-blocker) that competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
Oral: Initial 100 mg twice daily, titrate up to 200-400 mg twice daily; maximum 2400 mg/day. IV: 20 mg slow IV over 2 minutes, then 40-80 mg every 10 minutes as needed up to 300 mg total; or continuous IV infusion at 0.5-2 mg/min.
40 to 80 mg orally once daily, may be increased at 3-7 day intervals up to 240 mg once daily.
None Documented
None Documented
Clinical Note
moderateNadolol + Digitoxin
"Nadolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateNadolol + Deslanoside
"Nadolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateNadolol + Acetyldigitoxin
"Nadolol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateNadolol + Ouabain
"Nadolol may increase the bradycardic activities of Ouabain."
Terminal elimination half-life: 6-8 hours. In renal impairment, half-life may be slightly prolonged but not clinically significant; in hepatic impairment, half-life may be significantly prolonged.
Terminal elimination half-life: 14–24 hours (average 20 hours); prolonged in renal impairment (up to 45 hours) allowing once-daily dosing
Primarily hepatic metabolism; ~5% excreted unchanged in urine; ~55-60% as glucuronide conjugates in urine; fecal excretion <5%.
Renal (unchanged drug) 75-85%; fecal/biliary <5%
Category A/B
Category C
Alpha/Beta-Blocker
Beta-Blocker